839 results on '"Burman, Joachim"'
Search Results
2. Cerebrospinal fluid and plasma concentrations of the inflammatory marker soluble CD27 in a large surgical population
3. Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases
4. Image-derived input functions from dynamic 15O–water PET scans using penalised reconstruction
5. Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation
6. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
7. Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis
8. COVID-19–Related Enhancement for the COMBAT-MS Study
9. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
10. Experiences in implementing immunopsychiatry in real life
11. Disease phenotype prediction in multiple sclerosis
12. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
13. Cerebrospinal fluid and plasma concentrations of the inflammatory marker sCD27 in a large surgical population
14. Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis
15. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
16. Distribution of five clinically important neuroglial proteins in the human brain
17. Evaluation of polarity switching for untargeted lipidomics using liquid chromatography coupled to high resolution mass spectrometry
18. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
19. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
20. Conformal prediction enables disease course prediction and allows individualized diagnostic uncertainty in multiple sclerosis
21. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study
22. Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study
23. New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis
24. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis : A qualitative interview study
25. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
26. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : an observational cohort study
27. COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
28. Immune Mechanisms of Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
29. Multiple Sclerosis
30. Autologous Hematopoietic Stem Cell Transplantation for Relapsing-Remitting Multiple Sclerosis
31. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
32. Antibody‐positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case series.
33. Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation
34. Damage markers in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease
35. Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid
36. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis diseasemodulating therapy.
37. Cerebral blood flow measurements with 15O-water PET using a non-invasive machine-learning-derived arterial input function
38. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
39. CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
40. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
41. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis
42. Blogs cannot separate wheat from chaff
43. Treatment of epilepsy in multiple sclerosis
44. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
45. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab
46. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
47. Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry
48. Chapter 12 - Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be reestablished?
49. Chapter 13 - Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Is it CIDP?
50. Chapter 15 - Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.